
    
      This study is designed to provide pharmacokinetic (PK) data with respect to the relative
      systemic exposure to bimatoprost and bimatoprost acid after administration of a single 13 mg
      Bimatoprost Ocular Insert for 1 week in medically stable adult subjects with or without
      primary open angle glaucoma (POAG) or ocular hypertension (OHT).
    
  